Chiari Malformation Market Research Report- Forecast to 2027

Chiari Malformation Market Research Report: By Type (Type I, Type Ii, Type Iii) Treatment (Medication And Surgical Treatment), Diagnosis (X-Ray, Ct Scan, And Mri), End-Users (Hospitals & Surgical Centers, And Specialty Clinics) - Forecast Till 2027

ID: MRFR/Pharma/4177-HCR | | Region: Global | 105 pages

Chiari Malformation Market Scenario:


Chiari Malformation is a malformation or structural defect in which the brain tissue extends into the spinal canal. It occurs in the base of the skull and cerebellum (part of the brain that controls balance). Chiari malformations develop when part of the skull is smaller than the usual size, which forces the cerebellum to be pushed down into the foramen magnum and spinal canal.


Chiari Malformation can be caused by various reasons. Primarily it occurs due to improper fetal development which can be a result of genetic mutations or a maternal diet that was devoid of certain vitamins or nutrients. Additionally, traumatic injury, disease, or infection can lead to Chiari Malformation.


The Chiari Malformation market is estimated to lead a healthy growth. The Chiari Malformation market is majorly driven by the increasing geriatric population, rising global population, and rising injuries and infections due to road mishaps. According to the U.S. Population Reference Bureau, the number of Americans aged 65 and older is projected to be 98 million by 2060 from 46 million as of 2014. Similarly, the 65-and-older age group will rise to nearly 24 % by 2030 from 15 % as of 2015.


The Chiari Malformation market is expected to grow at a CAGR of 8.2% during the forecast period.


Figure: Global Chiari Malformation market, by region, 2017 (%)


 Chiari Malformation market


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, market research future analysis, annual report, white paper, company presentation


Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Segments 


The chiari malformations infection market is segmented on the basis of type, treatment, diagnosis, and end-users.


On the basis of the type, the chiari malformations infection market is segmented type I, type II, type III, type IV. On the basis of treatment, the market is segmented into Medications and Surgery. Surgery is further sub-segmented into Posterior fossa decompression, Electrocautery, and Spinal laminectomy.


On the basis of diagnosis, the chiari malformations infection market is segmented into X-Ray, CT scan, and MRI.


On the basis of end user the chiari malformations infection market is segmented into hospitals & surgical centres, research Institutes, and specialty clinics.


Research Methodology: Chiari Malformation market Research Methodology


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, market research future analysis, annual report, white paper, company presentation


Regional Analysis


North America holds the maximum share of Chiari Malformation market in the Americas region. On a regional basis, Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. Increasing number of geriatric population and growing diabetic mass has increased the scope of the Chiari Malformation  market in North America.


Europe accounts for the second largest share in the Chiari Malformation market. The European market is expected to grow a steady growth during the forecasted period.Factors such as government initiatives to enhance and develop new products, educate masses regarding rare diseases and campaigns to raise awarness regarding neurological disorders is fuelling the growth of Chiari Malformation market.


Asia Pacific is expected to be the fastest growing market due to increasing incidence of chronic diseases. India is the fastest growing region owing to an rising population. Additionally, rising awareness about the health and availability of new treatment methods is likely to drive the chiari malformations infection market in this region.


The Middle East & Africa is expected to show slow and steady growth in the chiari malformations infection market. Major factors that are hampering the growth are lack of awareness regarding rare diseases, and  limited access and affordibility  of treatment facilities. In the Middle East, United Arab Emirates  has garnered the largest market share owing to the development of healthcare infrastructure and rising number of specialty care centers.


Key Players                                                                                                         


Some of the key players in chiari malformations infection market are Abbott Laboratories, Inc., Becton, Dickinson and Company, Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi-Aventis, and GlaxoSmithKline among others.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   8.2% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, Diagnosis, and End-users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott Laboratories, Inc., Becton, Dickinson and Company, Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi-Aventis, and GlaxoSmithKline among others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing geriatric population
  • Rising global population
  • Rising injuries and infections due to road mishaps


  • Speak to Analyst Ask for Customization

    Table of Content


    1. Report Prologue

    2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    6. Global Chiari malformations Market, by Type

    6.1 Introduction

    6.2 Type I

    6.2.1 Market Estimates & Forecast, 2020-2027

    6.3 Type II

    6.3.1 Market Estimates & Forecast, 2020-2027

    6.4 Type III

    6.4.1 Market Estimates & Forecast, 2020-2027

    6.5 Type IV

    6.5.1 Market Estimates & Forecast, 2020-2027

    7. Global Chiari malformations Market, by Treatment

    7.1 Introduction

    7.2 Medications

    7.2.1 Market Estimates & Forecast, 2020-2027

    7.3 Surgery

    7.3.1 Posterior fossa decompression

    7.3.2 Electrocautery

    7.3.3 Spinal laminectomy

    7.3.4 Market Estimates & Forecast, 2020-2027

    8. Global Chiari malformations Market, by Diagnosis

    8.1 Introduction

    8.2 X-Ray

    8.2.1 Market Estimates & Forecast, 2020-2027

    8.3 CT Scan

    8.3.1 Market Estimates & Forecast, 2020-2027

    8.4 MRI

    8.4.1 Market Estimates & Forecast, 2020-2027

    9. Global Chiari malformations Market, by End User

    9.1 Introduction

    9.2 Hospitals & Surgical Centres

    8.2.1 Market Estimates & Forecast, 2020-2027

    8.3 Research Institutes

    8.3.1 Market Estimates & Forecast, 2020-2027

    8.4 Specialty clinics

    8.4.1 Market Estimates & Forecast, 2020-2027

    9 Global Chiari malformations Market, by Region

    9.1 Introduction

    9.2 Americas

    9.2.1 North America

    9.2.1.1 U.S.

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 U.K.

    9.3.1.4 Italy

    9.3.1.5 Spain

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia Pacific

    9.5 The The Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of the The Middle East & Africa

    10 Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    11 Company Profiles

    11.1 Abbott Laboratories, Inc.,

    11.1.1 Company Overview

    11.1.2 Product Overview

    11.1.3 Financials

    11.1.4 SWOT Analysis

    11.2 Becton, Dickinson and Company

    11.2.1 Company Overview

    11.2.2 Product Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 Novartis AG

    11.3.1 Company Overview

    11.3.2 Product Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Johnson & Johnson

    11.4.1 Company Overview

    11.4.2 Product/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Pfizer, Inc.

    11.5.1 Company Overview

    11.5.2 Product Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.6 Sanofi-Aventis

    11.6.1 Company Overview

    11.6.2 Product Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.7 GlaxoSmithKline

    11.7.1 Overview

    11.7.2 Product Overview

    11.7.3 Financials

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 Others

    12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s View Point

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Prediction of Pharmaceutical Industry

    13 Appendix

    LIST OF TABLES

    Table 1 Chiari malformations Industry Synopsis, 2020-2027

    Table 2 Global Chiari malformations Market Estimates and Forecast, 2020-2027, (USD Million)

    Table 3 Global Chiari malformations Market by Region, 2020-2027, (USD Million)

    Table 5 Global Chiari malformations Market by Treatment, 2020-2027, (USD Million)

    Table 6 Global Chiari malformations Market by Diagnosis, 2020-2027, (USD Million)

    Table 7 Global Chiari malformations Market by End Users, 2020-2027, (USD Million)

    Table 8 North America Chiari malformations Market by Treatment, 2020-2027, (USD Million)

    Table 9 North America Chiari malformations Market by Daignosis, 2020-2027, (USD Million)

    Table 10 North America Chiari malformations Market by End Users, 2020-2027, (USD Million)

    Table 11 US Chiari malformations Market by Treatment, 2020-2027, (USD Million)

    Table 12 US Chiari malformations Market by Daignosis, 2020-2027, (USD Million)

    Table 13 US Chiari malformations Market by End Users, 2020-2027, (USD Million)

    Table 14 Canada Chiari malformations Market by Treatment, 2020-2027, (USD Million)

    Table 15 Canada Chiari malformations Market by Daignosis, 2020-2027, (USD Million)

    Table 16 Canada Chiari malformations Market by End Users, 2020-2027, (USD Million)

    Table 17 South America Chiari malformations Market by Treatment, 2020-2027, (USD Million)

    Table 18 South America Chiari malformations Market by Daignosis, 2020-2027, (USD Million)

    Table 19 South America Chiari malformations Market by End Users, 2020-2027, (USD Million)

    Table 20 Europe Chiari malformations Market by Treatment, 2020-2027, (USD Million)

    Table 21 Europe Chiari malformations Market by Daignosis, 2020-2027, (USD Million)

    Table 22 Europe Chiari malformations Market by End Users, 2020-2027, (USD Million)

    Table 23 Western Europe Chiari malformations Market by Treatment, 2020-2027, (USD Million)

    Table 24 Western Europe Chiari malformations Market by Daignosis, 2020-2027, (USD Million)

    Table 25 Western Europe Chiari malformations Market by End Users, 2020-2027, (USD Million)

    Table 26 Eastern Europe Chiari malformations Market by Treatment, 2020-2027, (USD Million)

    Table 27 Eastern Europe Chiari malformations Market by Daignosis, 2020-2027, (USD Million)

    Table 28 Eastern Europe Chiari malformations Market by End Users, 2020-2027, (USD Million)

    Table 29 Asia Pacific Chiari malformations Market by Treatment, 2020-2027, (USD Million)

    Table 30 Asia Pacific Chiari malformations Market by Daignosis, 2020-2027, (USD Million)

    Table 31 Asia Pacific Chiari malformations Market by End Users, 2020-2027, (USD Million)

    Table 32 The Middle East & Africa Chiari malformations Market by Treatment, 2020-2027, (USD Million)

    Table 33 The Middle East & Africa Chiari malformations Market by Daignosis, 2020-2027, (USD Million)

    Table 34 The Middle East & Africa Chiari malformations Market by End Users, 2020-2027, (USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Chiari malformations Market

    Figure 3 Segmentation Market Dynamics for Chiari malformations Market

    Figure 4 Global Chiari malformations Market Share, by Treatment 2020

    Figure 5 Global Chiari malformations Market Share, by Diagnosis 2020

    Figure 6 Global Chiari malformations Market Share, by End Users, 2020

    Figure 7 Global Chiari malformations Market Share, by Region, 2020

    Figure 8 North America Chiari malformations Market Share, by Country, 2020

    Figure 9 Europe Chiari malformations Market Share, by Country, 2020

    Figure 10 Asia Pacific Chiari malformations Market Share, by Country, 2020

    Figure 11 The Middle East & Africa Chiari malformations Market Share, by Country, 2020

    Figure 12 Global Chiari malformations Market: Company Share Analysis, 2020 (%)

    Figure 13 Abbott Laboratories, Inc: Key Financials

    Figure 14 Abbott Laboratories, Inc: Segmental Revenue

    Figure 16 Abbott Laboratories, Inc: Geographical Revenue

    Figure 17 Becton, Dickinson and Company: Key Financials

    Figure 18 Becton, Dickinson and Company: Segmental Revenue

    Figure 19 Becton, Dickinson and Company: Geographical Revenue

    Figure 20 Novartis AG: Key Financials

    Figure 21 Novartis AG: Segmental Revenue

    Figure 22 Novartis AG Geographical Revenue

    Figure 23 Pfizer: Key Financials

    Figure 24 Pfizer: Segmental Revenue

    Figure 25 Pfizer: Geographical Revenue

    Figure 26 Sanofi-Aventis: Key Financials

    Figure 27 Sanofi-Aventis: Segmental Revenue

    Figure 28 Sanofi-Aventis: Geographical Revenue

    Figure 29 GlaxoSmithKline: Key Financials

    Figure 30 GlaxoSmithKline: Segmental Revenue

    Figure 31 GlaxoSmithKline: Geographical Revenue

    Figure 32 Johnson & Johnson.: Key Financials

    Figure 33 Johnson & Johnson.: Segmental Revenue

    Figure 34 Johnson & Johnson.: Geographical Revenue